ProQR Therapeutics NV (NASDAQ:PRQR)
| 1.46 Delayed Data As of 3:59pm ET |  +0.21 / +16.80%Today’s Change | 0.74 Today|||52-Week Range 3.85 | -60.54% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $140.0M |
Company Description
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Contact Information
ProQR Therapeutics NV Zernikedreef 9 Leiden Zuid-holland 2333 CK |
Employees
Shareholders
| Mutual fund holders | 8.64% |
| Other institutional | 16.16% |
| Individual stakeholders | -- |
Top Executives
| Daniel Anton de Boer | Chief Executive Officer |
| Sheila Sponselee | Vice President, Head-People & Operations |
| Jurriaan Dekkers | Chief Financial Officer |
| Gerard J. Platenburg | Chief Scientific Officer |
| Andrew Morris | Vice President-Business Development |
